Industry Leaders Fireside Chat: Evaluating CAR-T in Comparison to Emerging Modalities to Refine Autoimmune Therapies Through Strategic Modality Selection

Time: 8:40 am
day: Conference Day 1 P1

Details:

  • Explore the efficacy of differing modalities to identify opportunities where we can learn from other modalities
  • Compare modalities in their affinity for targeting autoreactive cells to minimize side-effects and enhance safety
  • Identify autoimmune indications where CD-19-CARs are suboptimal to spotlight opportunities for alternative therapeutic modalities

Speakers:

Fred Aslan
Fred Aslan Fred Aslan, M.D. brings two decades of leadership in the life sciences industry as an executive, investor, and entrepreneur. Most recently, he served as President Read more
Samik Basu
Samik Basu
Jennifer Chow
Jennifer Chow Jennifer Chow is a pioneer in cell therapy, having led the launch of over 10 oncology therapeutics, including key CAR T cell therapies like Ide-cel, Read more
Naji Gehchan
Naji Gehchan Naji Gehchan, is Chief Medical and Development Officer at Kyverna Therapeutics, overseeing research, clinical development, regulatory, and medical affairs. He brings over 20 years of Read more
Clinton Weber
Clinton Weber